Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | GPR3 | P46089 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29717662 | 1.00 | MPI (0.46) | MPIMIFGPR3MEN1CYP3A4 | |
| SCHEMBL6121142 | 0.87 | MIF (0.41) | MPIMIFMEN1CYP3A4KMT2A | |
| SCHEMBL29795880 | 0.83 | MPI (0.46) | MPITDP1NPC1RAB9ASLC22A12 | |
| SCHEMBL1089262 | 0.83 | MPI (0.46) | MPITDP1NPC1RAB9ASLC22A12 | |
| SCHEMBL29116581 | 0.82 | TRPV1 (0.43) | MPIMIF | |
| SCHEMBL1020500 | 0.80 | P2RY6 (0.47) | MIFGPR3MEN1CYP3A4KMT2A | |
| SCHEMBL29444412 | 0.78 | MIF (0.50) | MIFMEN1CYP3A4KMT2ATP53 | |
| SCHEMBL16664372 | 0.77 | MPI (0.49) | MPIGPR3KIF11SLC22A12ALDH1A1 | |
| SCHEMBL28167311 | 0.77 | MPI (0.49) | MPIGPR3KIF11NPC1RAB9A | |
| SCHEMBL23558 | 0.77 | HTR3E (0.53) | MIFMEN1CYP3A4KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011315-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | PRISM MEDICINES, INC. | 2025-01-09 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11608329-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2023-03-21 | — | — | US | disclosed |
| CN-115279741-A | 4-phenyl-N- (phenyl) thiazol-2-amine derivatives and related compounds as Aryl Hydrocarbon Receptor (AHR) agonists for the treatment of, for example, angiogenesis-related disorders or inflammatory disorders | 医肯纳肿瘤学公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-109476696-B | Anti-trypanosome and anti-leishmania agents for animals and humans | 细胞基因公司 | 2022-06-10 | — | — | CN | disclosed |
| EP-3464287-B1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORP (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11344554-B2 | Animal and human anti-malarial agents | CELGENE CORPORATION (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3464287-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | Celgene Corporation (US) | 2019-04-10 | — | — | EP | disclosed |
| CN-109563095-A | Animal and people's anti-malarial agents | 细胞基因公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109476696-A | Anti-trypanosome and anti-leishmania agents for animals and humans | 细胞基因公司 | 2019-03-15 | — | — | CN | disclosed |
| US-20180280398-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORP (US) | 2018-10-04 | — | — | US | disclosed |
| US-20180280399-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORP (US) | 2018-10-04 | — | — | US | disclosed |
| US-10016436-B2 | Animal and human anti-malarial agents | CELGENE CORPORATION (US) | 2018-07-10 | — | — | US | disclosed |
| WO-2017210399-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORPORATION (US) | 2017-12-07 | — | — | WO | disclosed |
| US-20170348316-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORPORATION | 2017-12-07 | — | — | US | disclosed |
| US-20040116417-A1 | Thiohydantoins and use thereof for treating diabetes | LABORATOIRES FOURNIER SA (FR) | 2004-06-17 | — | — | US | disclosed |
| CN-1500081-A | Thiohydantonins and use thereof for treating diabetes | ʵ���Ҹ���Ү��˾ | 2004-05-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280399-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | TPMT, TYMP, ATIC | MPI 278/4885MIF 1152/4885GPR3 1323/4885 |
| US-20250011315-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | MPI 4409/4885MIF 2764/4885GPR3 65/4885 |
| US-11608329-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | MPI 4409/4885MIF 2764/4885GPR3 65/4885 |
| US-20170348316-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | HPRT1, NUDT1, UMPS | MPI 938/4885MIF 2233/4885GPR3 1036/4885 |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | MPI 4409/4885MIF 2764/4885GPR3 65/4885 |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | MPI 4409/4885MIF 2764/4885GPR3 65/4885 |
| US-10016436-B2 | Animal and human anti-malarial agents | HPRT1, NUDT1, UMPS | MPI 938/4885MIF 2233/4885GPR3 1036/4885 |
| US-11344554-B2 | Animal and human anti-malarial agents | HPRT1, UMPS, PNP | MPI 797/4885MIF 2997/4885GPR3 913/4885 |
| US-20180280398-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | HPRT1, UMPS, PNP | MPI 797/4885MIF 2997/4885GPR3 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.